PAYLESS COMPOUNDERS, LLC
Has PAYLESS COMPOUNDERS, LLC received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to PAYLESS COMPOUNDERS, LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 1 drug recall report for it naming semaglutide, the latest initiated Mar 6, 2026.
FDA records in this index name PAYLESS COMPOUNDERS, LLC on Mar 6, 2026.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 1
- Drugs named
- Semaglutide
- Latest record
- Mar 6, 2026
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Mar 6, 2026 | Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR | Lack of Assurance of Sterility | Class II | Ongoing | D-0471-2026 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.